-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13

Benzinga·08/28/2026 14:50:52
Listen to the news
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $9 to $13.